Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences
- 1 May 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (9) , 2944-2950
- https://doi.org/10.1158/1078-0432.ccr-05-2724
Abstract
Silibinin, a flavonolignan from milk thistle, has intestinal cancer chemopreventive efficacy in rodents. It is a strong antioxidant and modulates the insulin-like growth factor (IGF) system by increasing circulating levels of IGF-binding protein 3 (IGFBP-3) and decreasing levels of IGF-I. Here, the hypothesis was tested that administration of oral silibinin generates agent levels in human blood and colorectal and hepatic tissues consistent with pharmacologic activity. Patients with confirmed colorectal adenocarcinoma received silibinin formulated with phosphatidylcholine (silipide) at dosages of 360, 720, or 1,440 mg silibinin daily for 7 days. Blood and biopsy samples of normal and malignant colorectum or liver were obtained before dosing, and blood and colorectal or hepatic tissues were collected at resection surgery after the final silipide dose. Levels of silibinin were quantified by high-pressure liquid chromatography-UV, and plasma metabolites were identified by liquid chromatography-mass spectrometry. Blood levels of IGFBP-3, IGF-I, and the oxidative DNA damage pyrimidopurinone adduct of deoxyguanosine (M1dG) were determined. Repeated administration of silipide was safe and achieved levels of silibinin of 0.3 to 4 micromol/L in the plasma, 0.3 to 2.5 nmol/g tissue in the liver, and 20 to 141 nmol/g tissue in colorectal tissue. Silibinin monoglucuronide, silibinin diglucuronide, silibinin monosulfate, and silibinin glucuronide sulfate were identified in the plasma. Intervention with silipide did not affect circulating levels of IGFBP-3, IGF-I, or M1dG. The high silibinin levels achieved in the human colorectal mucosa after consumption of safe silibinin doses support its further exploration as a potential human colorectal cancer chemopreventive agent.Keywords
This publication has 27 references indexed in Scilit:
- Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former SmokersJournal of Clinical Oncology, 2005
- Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin)Carcinogenesis: Integrative Cancer Research, 2005
- Chemopreventive Effects of a Flavonoid Antioxidant Silymarin on N‐Butyl‐N‐(4‐ hydroxybutyl)nitrosamine‐induced Urinary Bladder Carcinogenesis in Male ICR MiceJapanese Journal of Cancer Research, 2002
- Anti-Angiogenic Potential of a Cancer Chemopreventive Flavonoid Antioxidant, Silymarin: Inhibition of Key Attributes of Vascular Endothelial Cells and Angiogenic Cytokine Secretion by Cancer Epithelial CellsBiochemical and Biophysical Research Communications, 2000
- The IGF axis and programmed cell deathImmunology & Cell Biology, 1999
- Skin Cancer Chemopreventive Effects of a Flavonoid Antioxidant Silymarin Are Mediated via Impairment of Receptor Tyrosine Kinase Signaling and Perturbation in Cell Cycle ProgressionBiochemical and Biophysical Research Communications, 1998
- Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjectsEuropean Journal of Drug Metabolism and Pharmacokinetics, 1990
- Studies on the Antioxidant and Free Radical Scavenging Properties of Idb 1016 A New Flavanolignan ComplexFree Radical Research Communications, 1990
- Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liverJournal of Hepatology, 1989
- Effect of Silymarin on Chemical, Functional, and Morphological Alterations of the LiverScandinavian Journal of Gastroenterology, 1982